XML 56 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Quarterly Financial Data
12 Months Ended
Jun. 30, 2012
Quarterly Financial Data
16. Quarterly Financial Data (unaudited)

The following table summarizes the quarterly results of operations for the years ended June 30, 2012 and 2011:

 

     Fiscal Year 2012  
     First Quarter
Ended
September 30,
2011 (1)
    Second Quarter
Ended
December 31,
2011 (2)
    Third Quarter
Ended
March 31,
2012
    Fourth Quarter
Ended
June  30,

2012
    Year Ended
June 30,
2012 (1, 2)
 

Total revenues

   $ 1,659      $ 630      $ 538      $ 699      $ 3,526   

Operating loss

     (2,531     (17,643     (2,727     (2,310     (25,211

Net loss

     (2,427     (17,460     (2,686     (2,262     (24,835
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share:

          

Basic and diluted

   $ (0.12   $ (0.84   $ (0.13   $ (0.11   $ (1.19
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average common shares:

          

Basic and diluted

     20,757        20,803        20,803        20,803        20,791   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

     Fiscal Year 2011  
     First Quarter
Ended
September 30,
2010
    Second Quarter
Ended
December 31,
2010
    Third Quarter
Ended
March 31,
2011
    Fourth Quarter
Ended
June 30,
2011 (3)
    Year Ended
June 30,
2011 (3)
 

Total revenues

   $ 476      $ 414      $ 360      $ 3,715      $ 4,965   

Operating loss

     (3,435     (3,121     (3,139     (308     (10,003

Net loss

     (3,108     (2,695     (2,685     (140     (8,628
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share:

          

Basic and diluted

   $ (0.17   $ (0.15   $ (0.13   $ (0.01   $ (0.44
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average common shares:

          

Basic and diluted

     18,531        18,531        20,177        20,745        19,489   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(1) Results for the first quarter of fiscal 2012 included $1.1 million of revenue related to the termination of a field-of-use license by Intrinsiq (see Note 3)

 

(2) Results for the second quarter of fiscal 2012 included a $14.8 million impairment write-down of finite-lived intangible assets (see Note 4).

 

(3) Results for the fourth quarter of fiscal 2011 included $3.3 million of revenue related to a material modification of the Pfizer collaborative research and license agreement in June 2011 (see Note 3).